AIM:AGL

ANGLE PLC

Market:

AIM

Market Cap:

£136.22 m

Price

78.85 GBX

Change

-0.19%

52 weeks high

85.00

52 weeks low

38.00

In brief

ANGLE PLC develops products for use in rare cell diagnostics that enable early, accurate identification of an individual’s condition for the prevention, treatment, and monitoring of disease.

In brief Deep dive Research Latest news Insight Interviews

Deep dive We explore the investor case for growth companies

ANGLE’s Parsortix liquid biopsy proving to be more than just a cancer detection device

parsortix

Snapshot

ANGLE is developing Parsortix blood test that can detect cancer
FDA submission underway after trial met objectives
Healthy cash balance
Other tests in development

Interviews

Retail & consumer Investor Update: Endorsement for Angle's liquid biopsy system Parsortix

on 21/6/19

Retail & consumer Investor Update: ANGLE reports positive data from Parsortix FDA clinical study

on 31/5/19

Industry & services ANGLE PLC - Proactive One2One investor forum May 2019

on 24/5/19

Retail & consumer Lookahead to Proactive Investors evening event Thursday May 23

on 17/5/19

Follow us on:

© Proactive Investors 2019.

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority. Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use.